RESUMO
PURPOSE: To investigate the correlation of inhaled nitric oxide (NO) on plasma levels of cardiac troponin I (cTnI) and von Willebrand factor (vWF), glycoprotein (GP) IIb/IIIa, granule membrane protein 140 (GMP-140) in rabbits with acute massive pulmonary embolism (PE). METHODS: Thirty apanese white rabbits were divided into 3 groups, thrombus were injected in model group (n = 10), NO were inhalated for 24 h after massive PE in NO group (n = 10), saline were injected in control group (n = 10). The concentrations of vWF, GP IIb/IIIa, GMP-140 and cTnI were tested at 4, 8, 12, 16, 20, and 24 h, Correlation analyses were conducted between cTnI and vWF, GP IIb/IIIa, and GMP-140 by Pearson's correlation. RESULTS: The concentration of cTnI and vWF, GP IIb/IIIa, and GMP-140 was increased in the model group, compared to control group. In the inhaled group, the concentrations of cTnI, vWF, GP IIb/IIIa, and GMP-140 were reduced compared to model group. There was a positive correlation between cTnI and vWF, GP IIb/IIIa, and GMP-140. CONCLUSION: Inhaled nitric oxide can lead to a decrease in levels of cardiac troponin I, von Willebrand factor, glycoprotein, and granule membrane protein 140, after an established myocardial damage, provoked by acute massive pulmonary embolism.
Assuntos
Óxido Nítrico/administração & dosagem , Selectina-P/sangue , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/análise , Embolia Pulmonar/sangue , Embolia Pulmonar/tratamento farmacológico , Troponina I/sangue , Fator de von Willebrand/análise , Administração por Inalação , Animais , Modelos Animais de Doenças , Ventrículos do Coração/patologia , Miocárdio/patologia , Selectina-P/efeitos dos fármacos , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/efeitos dos fármacos , Embolia Pulmonar/patologia , Coelhos , Valores de Referência , Reprodutibilidade dos Testes , Fatores de Tempo , Resultado do Tratamento , Troponina I/efeitos dos fármacos , Microtomografia por Raio-X , Fator de von Willebrand/efeitos dos fármacosRESUMO
Abstract Purpose: To investigate the correlation of inhaled nitric oxide (NO) on plasma levels of cardiac troponin I (cTnI) and von Willebrand factor (vWF), glycoprotein (GP) IIb/IIIa, granule membrane protein 140 (GMP-140) in rabbits with acute massive pulmonary embolism (PE). Methods: Thirty apanese white rabbits were divided into 3 groups, thrombus were injected in model group (n = 10), NO were inhalated for 24 h after massive PE in NO group (n = 10), saline were injected in control group (n = 10). The concentrations of vWF, GP IIb/IIIa, GMP-140 and cTnI were tested at 4, 8, 12, 16, 20, and 24 h, Correlation analyses were conducted between cTnI and vWF, GP IIb/IIIa, and GMP-140 by Pearson's correlation. Results: The concentration of cTnI and vWF, GP IIb/IIIa, and GMP-140 was increased in the model group, compared to control group. In the inhaled group, the concentrations of cTnI, vWF, GP IIb/IIIa, and GMP-140 were reduced compared to model group. There was a positive correlation between cTnI and vWF, GP IIb/IIIa, and GMP-140. Conclusion: Inhaled nitric oxide can lead to a decrease in levels of cardiac troponin I, von Willebrand factor, glycoprotein, and granule membrane protein 140, after an established myocardial damage, provoked by acute massive pulmonary embolism.
Assuntos
Animais , Coelhos , Embolia Pulmonar/sangue , Fator de von Willebrand/análise , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/análise , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/efeitos dos fármacos , Selectina-P/sangue , Troponina I/sangue , Óxido Nítrico/administração & dosagem , Embolia Pulmonar/patologia , Embolia Pulmonar/tratamento farmacológico , Valores de Referência , Fatores de Tempo , Administração por Inalação , Fator de von Willebrand/efeitos dos fármacos , Reprodutibilidade dos Testes , Resultado do Tratamento , Selectina-P/efeitos dos fármacos , Troponina I/efeitos dos fármacos , Modelos Animais de Doenças , Microtomografia por Raio-X , Ventrículos do Coração/patologia , Miocárdio/patologiaRESUMO
Platelet activation contributes to thrombotic events in cardiovascular disease. Acetylsalicylic acid (ASA) is used in combination with clopidogrel to reduce cardiovascular events. Lysine acetylsalicylate (L-ASA), also inhibits platelet activation with fewer gastrointestinal side effects than ASA. Dual therapy with L-ASA and clopidogrel may result in an antiplatelet effect with fewer side effects. We compared the antiplatelet effect of combined ASA/clopidogrel versus L-ASA/clopidogrel in healthy subjects. Fourteen volunteers (seven men and seven women, aged 25-45 years) received antiplatelet therapy during 14-day periods in the following sequence: 75 mg ASA; 160 mg L-ASA; 75 mg clopidogrel; 160 mg L-ASA plus 75 mg clopidogrel, and 75 mg ASA plus 75 mg clopidogrel. We evaluated platelet aggregation and glycoprotein IIb/IIIa activation. Our results show that administration of L-ASA/clopidogrel is as effective as ASA/clopidogrel combination.
Assuntos
Aspirina/análogos & derivados , Aspirina/administração & dosagem , Plaquetas/efeitos dos fármacos , Lisina/análogos & derivados , Inibidores da Agregação Plaquetária/administração & dosagem , Agregação Plaquetária/efeitos dos fármacos , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/biossíntese , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/efeitos dos fármacos , Ticlopidina/análogos & derivados , Adulto , Aspirina/uso terapêutico , Plaquetas/fisiologia , Clopidogrel , Quimioterapia Combinada , Feminino , Humanos , Lisina/administração & dosagem , Lisina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Inibidores da Agregação Plaquetária/uso terapêutico , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/fisiologia , Valores de Referência , Ticlopidina/administração & dosagem , Ticlopidina/uso terapêuticoRESUMO
O autor comparou, experimentalmente, a eficácia da droga abciximab, um antagonista do receptor da glicoproteína IIb/IIIa das plaquetas, na prevençäo da trombose nas microanastamoses arteriais em ratos Wistar.Utilizou 20 animais, dos quais 10, do grupo controle, receberam soluçäo salina e 10 receberam abciximab, na concentraçäo de 0, 8mg/Kg, injetados na veia femoral.Trinta minutos após a administraçäo da soluçäo salina ou abciximab, todos os animais foram submetidos ao mecanismo provocador de trombose vascular da artéria femoral do lado oposto ao utilizado para administraçäo da droga, por meio de um trauma externo promovido por aparelho IMPACTOR, desenvolvido pela New York University para padronizaçäo de lesäo da medula nervosa, o que padronizou a lesäo arterial. Todos os animais foram submetidos à microanastomose vascular com mononáilon 10-0, em pontos separados, no local do trauma externo.Foram realizados testes para analisar a perviabilidade vascular da artéria femoral no peíodo de 10, 20 e 30 minutos após o término da anastomose. Após este período, todas as artérias femorais submetidas à microanastomoses foram ressecadas e analisadas em microscopia óptica para avaliar a presença de formaçäo de trombos.Após a análise estatística dos dados, o autor conclui que o uso do antagonista do receptor da glicoproteína IIb/IIIa das plaquetas diminui a incidência de tromboses nas microanastomoses vasculares.